new_0222_0383|DAWN|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0383|DAWN|1|Day One Biopharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Day One Biopharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Day One Biopharmaceuticals Inc Inventories (Quarterly) (USD)|Day One Biopharmaceuticals Inc Net PP&E (Quarterly) (USD)|Day One Biopharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Day One Biopharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Day One Biopharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Day One Biopharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Day One Biopharmaceuticals Inc Total Deposits (Quarterly) (USD)|Day One Biopharmaceuticals Inc Book Value (Quarterly) (USD)|Day One Biopharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Day One Biopharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Day One Biopharmaceuticals Inc EV to Revenues|Day One Biopharmaceuticals Inc EV to Earnings|Day One Biopharmaceuticals Inc EV to Free Cash Flow|Day One Biopharmaceuticals Inc EV to Assets (Quarterly)|Day One Biopharmaceuticals Inc PS Ratio|Day One Biopharmaceuticals Inc PE Ratio|Day One Biopharmaceuticals Inc Price to Book Value|Day One Biopharmaceuticals Inc PEG Ratio|Day One Biopharmaceuticals Inc Debt to Equity Ratio|Day One Biopharmaceuticals Inc Dividend Yield|Day One Biopharmaceuticals Inc Shareholder Yield (TTM)|Day One Biopharmaceuticals Inc Percent of Shares Outstanding Short|Day One Biopharmaceuticals Inc Total Receivables (Quarterly) (USD)|Day One Biopharmaceuticals Inc Total Payables (Quarterly) (USD)|Day One Biopharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Day One Biopharmaceuticals Inc Return on Invested Capital|Day One Biopharmaceuticals Inc Quality Ratio Score|Day One Biopharmaceuticals Inc Momentum Score|Day One Biopharmaceuticals Inc Beta (1Y)|Day One Biopharmaceuticals Inc Sustainable Growth Rate (TTM)|Day One Biopharmaceuticals Inc Institutional Investor Ownership Percentage|Day One Biopharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Day One Biopharmaceuticals Inc Total Employees (Annual)|Day One Biopharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Day One Biopharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Day One Biopharmaceuticals Inc Shares Outstanding|Day One Biopharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Day One Biopharmaceuticals Inc Ordinary Shares Number (Quarterly)|Day One Biopharmaceuticals Inc Payout Ratio|Day One Biopharmaceuticals Inc Quick Ratio (Quarterly)|Day One Biopharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Day One Biopharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Day One Biopharmaceuticals Inc Effective Tax Rate (TTM)|Day One Biopharmaceuticals Inc Return on Equity|Day One Biopharmaceuticals Inc Net Income (TTM) (USD)|Day One Biopharmaceuticals Inc Revenue (TTM) (USD)|Day One Biopharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Day One Biopharmaceuticals Inc Revenue (Quarterly) (USD)|Day One Biopharmaceuticals Inc Gross Profit (Quarterly) (USD)|Day One Biopharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Day One Biopharmaceuticals Inc Net Income (Quarterly) (USD)|Day One Biopharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Day One Biopharmaceuticals Inc Price (USD)|Day One Biopharmaceuticals Inc Total Return Price (USD)|Day One Biopharmaceuticals Inc Enterprise Value (USD)|Day One Biopharmaceuticals Inc 30-Day Average Daily Volume|Day One Biopharmaceuticals Inc 1 Year Price Returns (Daily)|Day One Biopharmaceuticals Inc Short Interest|Day One Biopharmaceuticals Inc PE Ratio (Forward)|Day One Biopharmaceuticals Inc PE Ratio (Forward 1y)|Day One Biopharmaceuticals Inc PS Ratio (Forward)|Day One Biopharmaceuticals Inc PS Ratio (Forward 1y)|Day One Biopharmaceuticals Inc Quarterly EPS Estimates (USD)|Day One Biopharmaceuticals Inc Quarterly Revenue Estimates (USD)|Day One Biopharmaceuticals Inc Quarterly EPS Surprise|Day One Biopharmaceuticals Inc Quarterly Revenue Surprise|Day One Biopharmaceuticals Inc Quarterly Actual EPS (USD)|Day One Biopharmaceuticals Inc Quarterly Actual Revenue (USD)|Day One Biopharmaceuticals Inc Revenue Estimates for Current Fiscal Year (USD)|Day One Biopharmaceuticals Inc Revenue Estimates for Next Fiscal Year (USD)|Day One Biopharmaceuticals Inc Price Target (USD)|Day One Biopharmaceuticals Inc Consensus Recommendation|Day One Biopharmaceuticals Inc Price Target Num Estimates|Day One Biopharmaceuticals Inc EPS Estimates for Current Fiscal Year (USD)|Day One Biopharmaceuticals Inc EPS Estimates for Next Fiscal Year (USD)|Day One Biopharmaceuticals Inc Research and Development Expense (Quarterly) (USD)|Day One Biopharmaceuticals Inc Reconciled Depreciation (Quarterly) (USD)|Day One Biopharmaceuticals Inc Non-Operating Interest Expense (Quarterly) (USD)|Day One Biopharmaceuticals Inc Land and Improvements (Quarterly) (USD)|Day One Biopharmaceuticals Inc Buildings and Improvements (Quarterly) (USD)|Day One Biopharmaceuticals Inc Other Properties (Quarterly) (USD)|Day One Biopharmaceuticals Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0383|DAWN|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0383|DAWN|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0383|DAWN|5|91|91||91||91|91|91||91|91||||1.44324324324||||1.43827160494|||1.44324324324||15.5||91|91||||||30.625|91.3333333333|183|91.3333333333|91.3333333333|26.6666666667||91|||91.3333333333|91.4|||91|||||91.3333333333|91.3333333333|91.3333333333|1.44324324324|1.44324324324|1.44324324324|1.4358974359||15.5||||1.44117647059|91.5|91.5|92||92|92|47.3333333333|47.3333333333|47.3333333333|25.5|47.3333333333|28.4|35.5|91.3333333333|91.3333333333|91.3333333333|||91|91||
new_0222_0383|DAWN|6|3|3||3||3|3|3||3|3||||185||||162|||185||16||3|3||||||8|6|1|6|6|6||3|||6|5|||3|||||6|6|6|185|185|185|156||16||||34|6|6|1||1|1|3|3|3|8|3|5|4|6|6|6|||3|3||
new_0222_0383|DAWN|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0383|DAWN|202003||||||||||||||||||||||||||||||||||42.031||-0.0365|0.808||||||-0.0313|||||||||-1.992|-1.535|-0.003||||||||||||||||||||||||0.961|0.014|0.003||||||
new_0222_0383|DAWN|202006||||||||||||||||||||||||||||||||||42.031||-0.0419|0.872||||||-0.0397|||||||||-2.409|-1.76|-0.01||||||||||||||||||||||||1.437|0.046|0.01||||||
new_0222_0383|DAWN|202009||||||||||||||||||||||||||||||||||42.031||-0.0672|1.024||||||-0.0607|||||||||-3.842|-2.824|-0.009||||||||||||||||||||||||2.537|0.046|0.009||||||
new_0222_0383|DAWN|202012|45.071|43.728||0.483||99.866|1.996|97.87||-54.205|-56.842|||||||||||||||0.202|2|||||||42.031||-0.1835|1.979|||60.3374|||-0.1179||||-40.496|||||-35.6|-34.377|-0.008||||||||||||||||||||||||4.165|0.049|0.008|||0.406|0.078||
new_0222_0383|DAWN|202103|158.755|154.87||0.435||229.729|3.066|226.663||-68.849|-72.024||||-43.7958|||||||||||0.686|2||||||12.8073|42.031|20|-0.38|3.454|60.4289||60.3374|||-0.38||||-54.143|||||-16.101|-15.182|-0.007|23.69|23.69|1276.6906|||||||||||||||||||||12.632|0.049|0.007|||0.363|0.078||
new_0222_0383|DAWN|202106|316.025|309.996||0.386||4.774|4.662|0.112||311.763|-86.308||||-27.054||||4.5231|||||1.4606||0.348|0.006||||||65.4663|22.6619||-5.04|5.525|61.9289||61.9289|||-5.04|-167.66|||-66.665|||||-15.473|-14.282|-0.007|22.77|22.77|1100.1251|68905.2667||904505|||||-0.305||-1552.5132||-5.04||||34.3333|1.5|3|-1.3961|-1.4304|9.914|0.049|0.007|||0.319|0.078|23.72|27.83
new_0222_0383|DAWN|202109|303.311|297.16||0.335||6.111|6.046|0.065||297.672|-105.548||||-23.7778||||4.9369|||||2.8738||0.683|0.006||||||64.6029|57.5142|42|-0.33|9.392|61.9289||61.9289|||-0.33|0.615|||-83.081|||||-19.24|-19.24|-0.006|23.73|23.73|1172.4128|153758.7333||1779703|||||-0.2774||-18.9446||-0.33||||35|1.5|3|-2.8733|-1.5933|9.849|0.05|0.006|||0.273|0.078|24.44|18.37
new_0222_0383|DAWN|202112|||||||||||||||-15.1366||||3.5055|||||5.5587|||||||||68.5642||||||||||||||||||||||16.85|16.85|746.342|308964.5333||3442471||||25.5944|-0.3467|||||||||1.5|||||||||||14.75|13.71
new_0222_0383|DAWN|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.48|||||||||||||||||||||
new_0222_0383|DAWN|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.49|||||||||||||||||||||
new_0222_0383|DAWN|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.385|||||||||||||||||||||
new_0222_0383|DAWN|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.41|||||||||||||||||||||